ABSTRACT
@#Objective Focusing on four types acute myeloid leukemia ( AML) fusion oncogenes，so as to explore the network difference with time series expression data and further identify important genes in networks． Methods Gene network difference analysis was conducted while focusing on the global attributes of the union network． The CompNet neighborhood similarity index ( CNSI) was adopted to assess network similarity．“fast-greedy”algorithm was used to detect communities based on the union network，and further identify hub genes． Ｒesults The CNSI value between NUP98-HOXA9-3 d and NUP98-HOXA9-8 d was 0． 73，while AML1-ETO-6 h and PML-ＲAＲA-6 h was 0．25． We identified ten AML associated genes and sev- en of them ( TNF，VEGFA，EP300，EGF，CD44，PTGS2，SMAD3) were reported in the literature． Conclu- sions The network difference analysis revealed the pattern and heterogeneity of AML gene expression change across different time points，and further provided target genes for efficient treatment of AML with different types of fusion oncogenes．
ABSTRACT
<p><b>BACKGROUND</b>While depression and certain cardiac biomarkers are associated with acute myocardial infarction (AMI), the relationship between them remains largely unexplored. We examined the association between depressive symptoms and biomarkers in patients with AMI.</p><p><b>METHODS</b>We performed a cross-sectional study using data from 103 patients with AMI between March 2013 and September 2014. The levels of depression, N-terminal proB-type natriuretic peptide (NT-proBNP), and troponin I (TnI) were measured at baseline. The patients were divided into two groups: those with depressive symptoms and those without depressive symptoms according to Zung Self-rating Depression Scale (SDS) score. Baseline comparisons between two groups were made using Student's t-test for continuous variables, Chi-square or Fisher's exact test for categorical variables, and Wilcoxon test for variables in skewed distribution. Binomial logistic regression and multivariate linear regression were performed to assess the association between depressive symptoms and biomarkers while adjusting for demographic and clinical variables.</p><p><b>RESULTS</b>Patients with depressive symptoms had significantly higher NT-proBNP levels as compared to patients without depressive symptoms (1135.0 [131.5, 2474.0] vs. 384.0 [133.0, 990.0], Z = -2.470, P = 0.013). Depressive symptoms were associated with higher NT-proBNP levels (odds ratio [OR] = 2.348, 95% CI: 1.344 to 4.103, P = 0.003) and higher body mass index (OR = 1.169, 95% confidence interval [CI]: 1.016 to 1.345, P = 0.029). The total SDS score was associated with the NT-proBNP level (β= 0.327, 95% CI: 1.674 to 6.119, P = 0.001) after multivariable adjustment. In particular, NT-proBNP was associated with three of the depressive dimensions, including core depression (β = 0.299, 95% CI: 0.551 to 2.428, P = 0.002), cognitive depression (β = 0.320, 95% CI: 0.476 to 1.811, P = 0.001), and somatic depression (β = 0.333, 95% CI: 0.240 to 0.847, P = 0.001). Neither the overall depressive symptomatology nor the individual depressive dimensions were associated with TnI levels.</p><p><b>CONCLUSIONS</b>Depressive symptoms, especially core depression, cognitive depression, and somatic depression, were related to high NT-proBNP levels in patients with AMI.</p>